key: cord-0262561-wx9ka5vl authors: Huang, W.; Xiao, J.; Ji, J.; Chen, L.-W. title: Association of lipid-lowering drugs with COVID-19 outcomes: A Mendelian Randomization study date: 2021-07-24 journal: nan DOI: 10.1101/2021.07.20.21260813 sha: 9309a017316813080871e0975e8c7f42d99262d6 doc_id: 262561 cord_uid: wx9ka5vl Background: Lipid metabolism plays an important role in viral infections. Large cohort study suggested a protective potential of lipid-lowering drugs in COVID-19 outcomes, but the nature of observational study precludes it to draw a causal inference. Objectives: To assess the causal effect of lipid-lowering drugs (HMGCR inhibitors, PCSK9 inhibitors and NPC1L1 inhibitors) on COVID-19 outcomes using 2-sample Mendelian Randomization (MR) study. Methods: We used two kinds of genetic instruments to proxy the exposure of lipid-lowering drugs, including expression quantitative trait loci (eQTLs) of drugs target genes, and genetic variants within or nearby drugs target genes associated with low-density lipoprotein (LDL) cholesterol from genome-wide association study (GWAS). GWASs of COVID-19 outcomes (susceptibility, hospitalization and very severe disease) were obtained from the COVID-19 Host Genetics Initiative. Summary-data-based MR (SMR) and inverse-variance weighted MR (IVW-MR) were used to calculate the effect estimates. Results: SMR analysis found that a higher expression of HMGCR was associated with a higher risk of COVID-19 hospitalization (OR=1.38, 95%CI=1.06-1.81; P=0.019). Similarly, IVW-MR analysis observed a positive association between HMGCR-mediated LDL cholesterol and COVID-19 hospitalization (OR=1.32, 95%CI=1.00-1.74; P=0.049). No consistent evidence from both SMR and IVW-MR analyses was found for the association of HMGCR inhibitors with COVID-19 susceptibility or very severe disease, or for the association of PCSK9 inhibitors and NPC1L1 inhibitor with COVID-19 outcomes. Conclusions: In this 2-sample MR study, we found potential causal evidence that HMGCR inhibitors could reduce the risk of COVID-19 hospitalization. Further research is needed to explore the therapeutic role of statins for COVID-19. The COVID-19 pandemic has caused millions of infections and deaths, which is caused by 2 a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 3 Lacking of drugs specifically targeted to SARS-CoV-2 infection has led to a great interest 4 to identify drugs that can be repurposed to reduce the infection and mortality of the disease. 5 Available studies have suggested an important role of lipid metabolism in viral infections, 6 including in the pathogenesis of SARS-CoV-2 infection (1) . The plausible mechanisms 7 include the involvement of host lipids in the virus life cycle, the influence of cholesterol 8 on the immune cell functions, interfering with the mevalonate pathway, and so on (1). Such 9 evidence indicates the potential protective effect of lipid-lowering drugs against COVID-10 19. HMG-CoA Reductase (HMGCR) inhibitors, known as statins, are the most commonly-11 used class of lipid-lowering drugs, which have a couple of predominant merits, such as the 12 well-proven safety, low cost, and pleiotropic effects. Therefore, a number of observational 13 studies have investigated the association between statins and COVID-19 outcomes, but 14 generating mixed results (2) (3) (4) (5) (6) . What's more, confounding bias and reverse causation 15 cannot be avoided in most of these studies. 16 Mendelian randomization (MR) study uses genetic variants as an instrument to perform 17 causal inference between an exposure and an outcome, which could determine whether an 18 observational association is consistent with a causal effect (7) . Confounding bias can be 19 minimized in MR study because genetic variants are randomly assigned to the individual 20 at birth. Similarly, reverse causation can be avoided because genetic variants are assigned 21 prior to the development of disease. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 24, 2021. ; https://doi.org/10.1101/2021.07.20.21260813 doi: medRxiv preprint Therefore, we performed 2-sample MR analysis in this study to test the association of 1 several FDA-approved lipid-lowering drugs (HMGCR inhibitors, PCSK9 inhibitors and 2 NPC1L1 inhibitors) with COVID-19 outcomes (susceptibility, hospitalization and very 3 severe disease). Table 1 ). All these studies had been approved by the relevant 10 institutional review boards and participants had provided informed consents. 12 Three classes of FDA-approved lipid-lowering drugs were included as exposures in this 13 study: HMGCR inhibitors (i.e., statins), proprotein convertase subtilisin/kexin type 9 14 (PCSK9) inhibitors (i.e., alirocumab and evolocumab), and niemann-Pick C1 like 1 15 (NPC1L1) inhibitor (i.e., ezetimibe). 16 As shown in Table 1 , we used available eQTLs for drugs target genes (i.e., HMGCR, 17 PCSK9, NPC1L1) as the proxy of exposure to each lipid-lowering drug. The eQTLs 18 summary-level data was obtained from eQTLGen Consortium (https://www.eqtlgen.org/) 19 or GTEx Consortium V8 (https://gtexportal.org/home/). We identified common (minor 20 allele frequency (MAF) >1%) eQTLs single-nucleotide polymorphisms (SNPs) 21 significantly (p<5.0 × 10 -8 ) associated with the expression of HMGCR or PCSK9 in blood, 22 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 24, 2021. ; https://doi.org/10.1101/2021.07.20.21260813 doi: medRxiv preprint and the expression of NPC1L1 in adipose subcutaneous tissue as there are no eQTLs in 1 blood or other tissues available at a significance level for NPC1L1. Only cis-eQTLs were 2 included to generate genetic instruments in this study, which were defined as eQTLs within 3 1 Mb on either side of the encoded gene. 4 Secondly, to validate the observed association using the eQTLs as an instrument, we 5 additionally proposed an instrument by selecting SNPs within 100 kb windows from target 6 gene of each drug that were associated with LDL cholesterol level at a genome-wide 7 significance level (p<5.0 × 10 -8 ) to proxy the exposure of lipid-lowering drugs. A GWAS 8 summary data of LDL cholesterol levels from the Global Lipids Genetics Consortium was 9 used to identify these SNPs, where only common SNPs (MAF>1%) were included (8) . Seven SNPs within 100 kb windows from HMGCR gene were selected for proxying 11 HMGCR inhibitors, 12 SNPs from PCSK9 gene identified for PCSK9 inhibitors, and three 12 SNPs from NPC1L1 gene selected for NPC1L1 inhibitor. To maximize the strength of the 13 instrument for each drug, SNPs used as instruments were allowed to be in low weak linkage 14 disequilibrium (r 2 <0.30) with each other. 15 Outcome sources 16 GWAS summary-level data for COVID-19 outcomes were obtained from the COVID-19 17 Host Genetics Initiative V4 (https://www.covid19hg.org/ ) (9). The study population was 18 restricted to individuals with European ancestry, including meta-analyses of GWASs 19 containing up to 22 cohorts from 11 countries. GWAS from these cohorts used a model 20 adjusted for age, sex, age × age, age × sex, genetic principal components, and study-21 specific covariates. A COVID-19 case was confirmed by lab or self-reported infections, or 22 electronic health records of infections. The susceptibility outcome was measured by 23 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 24, 2021. ; https://doi.org/10.1101/2021.07.20.21260813 doi: medRxiv preprint comparing COVID-19 cases and controls who did not have a history of COVID-19. The 1 hospitalized outcome was measured by comparing COVID-19 hospitalized cases and 2 controls who were never admitted to the hospital due to COVID-19, including individuals 3 without COVID-19. The severe disease outcome was measured by comparing COVID-19 4 cases who died or required respiratory support and controls without severe COVID-19, 5 including individuals without COVID-19. We included individuals without COVID-19 as 6 controls for all outcomes to decrease collider bias and allow for population-level 7 comparisons (10,11). The strength of SNPs used as the instrument was assessed using the F-statistic, and we 20 included SNPs with an F-statistic of >10 to minimize weak instrument bias (13) . Positive 21 control analyses were performed for validation of both genetic instruments. Since lowering 22 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 24, 2021. interest with coronary heart disease because coronary heart disease is the main indication 5 of lipid-lowering drugs. 6 For SMR method, the heterogeneity in dependent instruments (HEIDI) test was used to test 7 if the observed association between gene expression and outcome was due to a linkage 8 scenario, which was performed in the SMR software (12) . As recommended by the authors, 9 the HEIDI test of P<0.01 indicates that association is probably due to linkage (12) . One 10 SNP could be related to the expression of more than one gene, leading to the presence of 11 horizontal pleiotropy. To assess the risk of horizontal pleiotropy, we identified other nearby 12 genes (within a 1Mb window) with significant association with the genetic instrumental 13 variant, and performed SMR analysis to examine if the expression of these genes was 14 related to the COVID-19 outcomes. 15 For IVW-MR method, we tested the heterogeneity by using a Cochran Q test, where P<0.05 16 indicates the evidence of heterogeneity (14) . MR-Egger regression and Mendelian (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. To account for multiple testing correction, Bonferroni correction was used to adjust the 3 thresholds of significance level, with a strong evidence of P<0.006 (3 exposures and 3 4 outcomes) and a suggestive evidence of 0.006≤P<0.05. Genetic instruments selection and COVID-19 outcomes 7 A total of 168, 24, and 11 cis-eQTLs were identified from eQTLGen or GTEx Consortium 8 for drugs target gene HMGCR, PCSK9, and NPC1L1, respectively, and the most 9 significant cis-eQTL SNP was selected as a genetic instrument for target gene of each drug 10 ( 15 Positive control study showed significant associations between exposure to each drug and 16 LDL cholesterol when using eQTLs-proposed instruments (Supplementary Table 5) , as 17 well as between exposure to each drug and coronary heart disease when using LDL (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 3 In Figure 1 and Supplementary Table 2 , results from SMR analysis found a suggestive 4 evidence for the association of the increased expression of HMGCR gene in blood (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table 8 ). 12 For IVW-MR analysis, Cochran Q test did not found evidence of heterogeneity for all 13 reported results (All P<0.05; Supplementary Table 4 ). Both the intercept term in MR- 14 Egger regression and MR-PRESSO analysis suggested that horizontal pleiotropy played a 15 small role in the reported results (All P<0.05; Supplementary Table 4) . 16 The present MR study provided a suggestive evidence regarding the positive association (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 24, 2021. ; https://doi.org/10.1101/2021.07.20.21260813 doi: medRxiv preprint 13 supported when using LDL cholesterol GWAS as an instrument. A strong evidence was 1 observed for the protective effect of NPC1L1-mediated lower level of LDL cholesterol on 2 COVID-19 susceptibility, but there was no evidence for the association of NPC1L1 3 expression and COVID-19 outcomes. 4 Compared to develop a new drug, repurposing an old drug is much more economical and 5 time-saving, in particular, the importance is further highlighted during a pandemic. 1,17,19) . 12 Emerging observational studies have investigated if statins might benefit patients with 13 COVID-19 (2-6). A largest retrospective cohort study including 13,981 patients admitted 14 to hospital due to COVID-19 suggested a significant reduction in 28-day all-cause 15 mortality by 42% in the group with statins than patients without statins (2) . A meta-analysis 16 with 8,990 COVID-19 patients also found a 30% lower risk of fatal or severe disease (3). However, a Danish nationwide cohort study with 4,842 COVID-19 patients and a meta-18 analysis with 3,449 COVID-19 patients did not found the association between statins use 19 and improved COVID-19 outcomes (5, 6) . In addition, in these studies, considerable 20 differences in clinical characteristics cannot be avoided between patients with and without 21 statins, and causal inference is not allowed due to the retrospective nature of observational 22 studies. 23 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 24, 2021. ; https://doi.org/10.1101/2021.07.20.21260813 doi: medRxiv preprint As a genetic epidemiological method, MR study could overcome the limitations of 1 traditional observational studies. In this MR study, we used genetic variants related to 2 HMGCR expression or HMGCR-mediated LDL cholesterol as instruments to proxy the 3 exposure of statins. Both analyses found a suggestive evidence that statins could reduce 4 the risk of COVID-19 hospitalization, rather than COVID-19 susceptibility and very severe 5 outcome. Although strong evidence is lacking, these results provided a causal evidence 6 supporting the finding from the largest cohort study (2) , which calls for additional 7 observational studies in different populations, mechanistic studies, and randomized 8 controlled studies to examine its potential effect against COVID-19. Besides, although no 9 association was found between NPC1L1 expression in adipose subcutaneous and COVID-10 19 outcomes, there was a strong evidence of the association between NPC1L1-mediated 11 LDL cholesterol and COVID-19 susceptibility. The effect of NPC1L1 inhibitor on 12 COVID-19 susceptibility may be worth further studies as well. 13 Study strengths 14 The main strength of our study is the use of genetic instruments to proxy drug exposure, 15 which could minimize confounding bias and avoid reverse causation. Besides, we used two 16 different kinds of genetic instruments to proxy the studied drug, which contributes to 17 validate the effect estimates from each other. And a number of sensitivity analyses have 18 been performed to test the efficacy of genetic instruments and the assumptions of MR study. In addition, we used large eQTL summary data of drugs target genes and GWAS summary 20 data of LDL cholesterol and COVID-19 outcomes, which could ensure statistical power. 22 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 24, 2021. ; https://doi.org/10.1101/2021.07.20.21260813 doi: medRxiv preprint 1 NPC1L1, so we were not allowed to explore the association between NPC1L1 expression 2 in blood and COVID-19 outcomes. Besides, there are no available eQTLs in lung for 3 HMGCR, which might provide more convincing evidence of the association between 4 HMGCR inhibitors and COVID hospitalization. Secondly, the effect of statins probably 5 varies between subgroups, for example, it may be more effective in patients with chronic 6 diseases (e.g., coronary heart disease). However, the use of summary-level data did not 7 allow us to perform subgroup analyses, so further MR study with individual-level data is 8 needed to provide more detailed information. Thirdly, the Bonferroni correction for 9 multiple tests suggests that we cannot rule out the false-positive possibility for the finding 10 of the protective effect of statins on COVID hospitalization. Fourthly, confounding bias 11 and/or horizontal pleiotropy cannot be completely excluded although we have performed 12 various sensitivity analyses to test the assumptions of MR study. In conclusion, this MR study provided potential causal evidence for the association 15 between statins exposure and the reduced risk of COVID-19 hospitalization. Further 16 research is called to confirm the association and the underlying mechanisms. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 24, 2021. ; https://doi.org/10.1101/2021.07.20.21260813 doi: medRxiv preprint IVW-MR, inverse-variance weighted Mendelian Randomization; NPC1L1, Niemann-Pick C1-Like 1; OR, odds ratio; PCSK9, Proprotein convertase subtilisin/kexin type 9. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 24, 2021. Lipid metabolism plays an important role in the viral infections, indicating the potential to be repurposed against COVID-19. However, previous observational studies yielded inconsistent findings. The present 2-sample Mendelian randomization study provides a suggestive evidence for the causal relationship between statins use and lower risk of COVID-19 hospitalization, which could overcome the limitations of observational study (i.e., confounding bias and reverse causation). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 24, 2021. ; https://doi.org/10.1101/2021.07.20.21260813 doi: medRxiv preprint Lipid homeostasis and mevalonate pathway in COVID-19: Basic concepts and potential therapeutic targets Progress in lipid research In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19 Cell metabolism Meta-analysis of Effect of Statins in Patients with COVID-19 The American journal of cardiology Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19 Statin therapy did not improve the in-hospital outcome of coronavirus disease 2019 (COVID-19) infection Association between statin use and outcomes in patients with coronavirus disease 2019 (COVID-19): a nationwide cohort study Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians Discovery and refinement of loci associated with lipid levels Nature genetics Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets Nature genetics Avoiding bias from weak instruments in Mendelian randomization studies International journal of epidemiology Measuring inconsistency in meta-analyses Interpreting findings from Mendelian randomization using the MR-Egger method European journal of epidemiology Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases Nature genetics No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted Abbreviations and Acronyms: eQTLs, expression quantitative trait loci GWAS, genome-wide association study in dependent instruments; HMGCR, HMG-CoA reductase; IVW-MR, inverse-variance weighted Mendelian Randomization; LDL, low-density lipoprotein; MR-PRESSO, Mendelian Randomization Pleiotropy RESidual Sum and Outlier; MAF, minor allele frequency <0.30), associated with LDL cholesterol (P < 5.0 × 10 -8 ), located within ±100 kb windows from HMGCR region PCSK9 inhibitors 24 common cis-eQTLs (MAF>1%) in blood for PCSK9 gene (P < 5.0 × 10 -8 ), top SNP: rs472495 12 common SNPs (MAF>1%) in low linkage disequilibrium (r 2 <0.30), associated with LDL cholesterol (P < 5.0 × 10 -8 ), located within ±100 kb windows from PCSK9 region NPC1L1 inhibitors 11 common cis-eQTLs (MAF>1%) in adipose subcutaneous tissue for NPC1L1 gene (P < 5.0 × 10 -8 ), top SNP: rs41279633 3 common SNPs (MAF>1%) in low linkage disequilibrium (r 2 <0.30), associated with LDL cholesterol (P < 5.0 × 10 -8 ), located within ±100 kb windows from NPC1L1 region Statistical analyses Primary analysis Summary-data-based Mendelian Randomization Inverse-variance weighted Mendelian Randomization Sensitivity analyses F-statistic Positive control analysis (LDL cholesterol used as outcome) Linkage disequilibrium test: HEIDI test Horizontal pleiotropy test: SMR association between expression of adjacent genes and outcome F-statistic Positive control analysis All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted July 24, 2021.